Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
15 September 2021Next earnings report:
27 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:55:28 GMTDividend
Analysts recommendations
Institutional Ownership
PRCT Latest News
Does PROCEPT BioRobotics Corporation (PRCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock. A selling stockholder also expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of the Company's common stock. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
PROCEPT BioRobotics PRCT stock is trading on Monday after the company released better-than-expected third-quarter earnings.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q3 2024 Earnings Conference Call October 28, 2024 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - Chief Executive Officer Sham Shiblaq - Chief Commercial Officer Kevin Waters - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Securities Brandon Vasquez - William Blair Richard Newitter - Truist Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Ryan Zimmerman - BTIG Brett Gasaway - Leerink Partners Operator Good morning and welcome to PROCEPT BioRobotics Third Quarter 2024 Earnings Conference Call. At this time all participants' are in a listen-only mode.
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.51 per share a year ago.
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024.
PROCEPT BioRobotics (PRCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
PROCEPT BioRobotics (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PROCEPT BioRobotics receives FDA's approval to begin a pivotal randomized clinical study to assess the use of Aquablation therapy in treating prostate cancer patients.
- 1(current)
- 2
What type of business is PROCEPT BioRobotics?
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
What sector is PROCEPT BioRobotics in?
PROCEPT BioRobotics is in the Healthcare sector
What industry is PROCEPT BioRobotics in?
PROCEPT BioRobotics is in the Medical Devices industry
What country is PROCEPT BioRobotics from?
PROCEPT BioRobotics is headquartered in United States
When did PROCEPT BioRobotics go public?
PROCEPT BioRobotics initial public offering (IPO) was on 15 September 2021
What is PROCEPT BioRobotics website?
https://www.procept-biorobotics.com
Is PROCEPT BioRobotics in the S&P 500?
No, PROCEPT BioRobotics is not included in the S&P 500 index
Is PROCEPT BioRobotics in the NASDAQ 100?
No, PROCEPT BioRobotics is not included in the NASDAQ 100 index
Is PROCEPT BioRobotics in the Dow Jones?
No, PROCEPT BioRobotics is not included in the Dow Jones index
When was PROCEPT BioRobotics the previous earnings report?
No data
When does PROCEPT BioRobotics earnings report?
The next expected earnings date for PROCEPT BioRobotics is 27 February 2025